clinical trial · NCT04984577
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
Nanjing Yoko Biomedical Co., Ltd.·phase2·suspended·n = 240
Acute Ischemic StrokeCompound Edaravone Injection-Low doseCompound Edaravone Injection-High doseEdaravone InjectionPlacebo injection
brief summary
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner. The study is also to examine the safety of compound Edaravone Injection for the AIS patients.
started
Nov 15, 2021
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Feb 20, 2024
official title
Phase II Trial of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke -- a Multi-center, Randomized, Double-blind, Parallel, Multi-doses and Active-controlled Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol